Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.

Get BBIO alerts

About Charles Homcy

Charles Homcy is recorded as Chairman and Board Member at BridgeBio Pharma, Inc. (BBIO) and Board Member at Maze Therapeutics, Inc. (MAZE) since January 1, 2018. The newest filing on record that lists Charles Homcy as Board Member at BridgeBio Pharma, Inc. (BBIO) is dated April 24, 2026. The newest filing on record that lists Charles Homcy as Chairman at BridgeBio Pharma, Inc. (BBIO) is dated April 30, 2021. The proxy statement of BridgeBio Pharma, Inc. reports total compensation of $1,855,805 for Charles Homcy in fiscal 2020, including a base salary of $500,000. Disclosed compensation is on record for 2 fiscal years. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Maze Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Brian Stephenson (CFO), Thomas Trimarchi (CFO and COO) and 7 others.

Affiliation history

Company network

Leadership on record at BridgeBio Pharma, Inc.

Leadership on record at Maze Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 BridgeBio Pharma, Inc. (BBIO) $500,000 $1,855,805
2019 BridgeBio Pharma, Inc. (BBIO) $513,808 $5,975,842

Recent activity

No call appearances or filed executive changes recorded yet.